Skip to main content
. 2020 Jul 23;9(8):2349. doi: 10.3390/jcm9082349

Table 1.

mtDNA variants identified by NGS in p.R453C-β-MHC isogenic lines used for HCM modeling (WT, healthy; het, heterozygous; HOM, homozygous; KO, knockout). In silico pathogenicity prediction algorithms used: § MitoTIP; * Polyphen-2; CAROL; APOGEE. Phenotypically severe hPSC-CM line is highlighted in red and less severe ones in green.

Isogenic hPSC-CM Set(s) Locus mtDNA Mutation Percent Heteroplasmy (WT-Het-HOM-KO) In silico Prediction (Score) Potential HCM Effect
AT1 MT-HV2, MT-OHR m.152T > C 99.9 (all lines) N/A
(non-coding)
Aggravator (present only in AT1s)
REBL-PAT + HUES7 MT-HV2, MT-OHR, MT-CSB2 m.309_310insCCT REBL-PAT: 28.9–26.4–27.2
HUES7: 17.4–13.8–15.6
N/A
(non-coding)
Protective (absent in AT1)
HUES7 MT-HV2, MT-OHR, MT-CSB2 m.309_310insCCCT 11.7–11.6–13.3 N/A
(non-coding)
Protective (absent in AT1)
AT1 + REBL-PAT + HUES7 MT-HV2, MT-OHR, MT-CSB2 m.310T > C AT1: 15.0–17.1–14.5–17.0;
REBL-PAT: 61.2–63.2–61.9;
HUES7: 61.6–56.4–57.6
N/A
(non-coding)
Protective (less prevalent in AT1)
AT1 + REBL-PAT + HUES7 MT-HV2, MT-OHR, MT-CSB2 m.310_311insC AT1: 67.8–64.2–65.6–63.9
REBL-PAT: 30.1–26.7–27.2
HUES7: 26.1–32.0–33.3
N/A
(non-coding)
Aggravator (more prevalent in AT1s)
AT1 MT-HV3 m.514_515delCA 60.1–53.5–53.6–53.7; N/A
(non-coding)
Aggravator only present in AT1s)
REBL-PAT MT-RNR2 m.2203G > A 14.5% N/A
(non-coding)
None: acquired during reprogramming
AT1 MT-RNR2 m.2525C > T Fibroblasts: 12.1%
iPSCs + iPSC-CMs: 99.9%
N/A
(non-coding)
None: increased upon nuclear reprogramming
AT1 + REBL-PAT + HUES7 MT-TA m.5597A > C AT1: 5.4–12.4–6.5–11.4;
REBL-PAT: 11.1–14.3–13.2;
HUES7: 24.8–7.8–8.8
Possibly pathogenic (73.80%) § None: acquired during reprogramming/culture
HUES7 MT-CO1 m.5938A > C 12.2–1.2–1.1 Probably damaging (1.000) *
Deleterious (1)
Neutral (0.45)
None: acquired during culture
REBL-PAT MT-HV1 m.16319G > A 99.7–99.7–99.6 N/A
(non-coding)
Protective (absent in AT1)